EIF5A marks an immune-inflamed epithelial state and restrains proliferation and migration in gastric cancer cells

Background Gastric cancer (GC), most frequently represented as stomach adenocarcinoma (STAD), is clinically and molecularly heterogeneous, and biomarkers linking tumor-cell state, immune context and therapeutic response are needed. EIF5A encodes a hypusine-modified translation factor with context-dependent functions in cancer, but its significance in GC remains insufficiently defined. Methods We integrated The Cancer Genome Atlas-STAD, Gene Expression Omnibus validation cohorts (GSE15459, GSE62254 and GSE84437), public immunotherapy resources, GSE183904 single-cell RNA-sequencing data, and matched somatic mutation, copy-number variation, DNA methylation, proteomic and intratumoral microbiome datasets. Samples were stratified by EIF5A expression. Survival, clinicopathological associations, tumor mutation burden (TMB), functional programs, immune features, upstream regulation and microbiome features were evaluated. EIF5A overexpression was further tested in EIF5A-low GC cell lines using qRT-PCR, CCK-8, colony formation, transwell migration and wound-healing assays. Results EIF5A expression was increased in immunotherapy responders and TMB-high tumors, with favorable survival associations in selected subgroups, particularly male patients, advanced-stage disease and diffuse-type tumors. EIF5A-high tumors showed epithelial differentiation, translation/proteostasis, cell-cycle and DNA damage surveillance programs, with reduced Epithelial-Mesenchymal Transition-, invasion- and focal adhesion-related signals at transcriptomic and proteomic levels. They also exhibited enhanced cytotoxic, checkpoint, T-cell and NK-cell signatures alongside Treg and exhaustion signals, indicating an immune-inflamed but regulated microenvironment. Copy-number and methylation alterations only partly explained EIF5A expression, while perturbation evidence and cross-cohort validation identified HMGA1 as a candidate upstream regulator. The HMGA1-EIF5A axis was associated with chemokine networks, immune infiltration and selective intratumoral microbial changes. Single-cell analysis localized EIF5A mainly to cycling and malignant epithelial cells, where it correlated with proliferation, glycolysis and hypoxia rather than epithelial-mesenchymal transition. EIF5A overexpression in HGC-27 and SNU-719 cells suppressed cell viability, colony formation, transwell migration and wound closure. Conclusions EIF5A marks an epithelial, immune-inflamed and relatively less invasive state in GC and may help refine biomarkers for prognosis and immunotherapy response. The HMGA1-EIF5A regulatory relationship and the suppressive effects of EIF5A overexpression support further mechanistic validation and therapeutic exploration, suggesting a potential anti-tumor role for EIF5A in GC.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11638300/v1
Primary Topic
Gastric Cancer Management and Outcomes
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

EIF5A marks an immune-inflamed epithelial state and restrains proliferation and migration in gastric cancer cells

Yanghui Wen, Kepu Zheng, Yunjie Chen, Feng Ren et al.
Research Square
Gastric Cancer Management and Outcomes
preprint

EIF5A marks an immune-inflamed epithelial state and restrains proliferation and migration in gastric cancer cells

Yanghui Wen, Kepu Zheng, Yunjie Chen, Feng Ren, Zhilin Liu
preprint en

Abstract

Background Gastric cancer (GC), most frequently represented as stomach adenocarcinoma (STAD), is clinically and molecularly heterogeneous, and biomarkers linking tumor-cell state, immune context and therapeutic response are needed. EIF5A encodes a hypusine-modified translation factor with context-dependent functions in cancer, but its significance in GC remains insufficiently defined. Methods We integrated The Cancer Genome Atlas-STAD, Gene Expression Omnibus validation cohorts (GSE15459, GSE62254 and GSE84437), public immunotherapy resources, GSE183904 single-cell RNA-sequencing data, and matched somatic mutation, copy-number variation, DNA methylation, proteomic and intratumoral microbiome datasets. Samples were stratified by EIF5A expression. Survival, clinicopathological associations, tumor mutation burden (TMB), functional programs, immune features, upstream regulation and microbiome features were evaluated. EIF5A overexpression was further tested in EIF5A-low GC cell lines using qRT-PCR, CCK-8, colony formation, transwell migration and wound-healing assays. Results EIF5A expression was increased in immunotherapy responders and TMB-high tumors, with favorable survival associations in selected subgroups, particularly male patients, advanced-stage disease and diffuse-type tumors. EIF5A-high tumors showed epithelial differentiation, translation/proteostasis, cell-cycle and DNA damage surveillance programs, with reduced Epithelial-Mesenchymal Transition-, invasion- and focal adhesion-related signals at transcriptomic and proteomic levels. They also exhibited enhanced cytotoxic, checkpoint, T-cell and NK-cell signatures alongside Treg and exhaustion signals, indicating an immune-inflamed but regulated microenvironment. Copy-number and methylation alterations only partly explained EIF5A expression, while perturbation evidence and cross-cohort validation identified HMGA1 as a candidate upstream regulator. The HMGA1-EIF5A axis was associated with chemokine networks, immune infiltration and selective intratumoral microbial changes. Single-cell analysis localized EIF5A mainly to cycling and malignant epithelial cells, where it correlated with proliferation, glycolysis and hypoxia rather than epithelial-mesenchymal transition. EIF5A overexpression in HGC-27 and SNU-719 cells suppressed cell viability, colony formation, transwell migration and wound closure. Conclusions EIF5A marks an epithelial, immune-inflamed and relatively less invasive state in GC and may help refine biomarkers for prognosis and immunotherapy response. The HMGA1-EIF5A regulatory relationship and the suppressive effects of EIF5A overexpression support further mechanistic validation and therapeutic exploration, suggesting a potential anti-tumor role for EIF5A in GC.

Research Square
Ningbo No. 2 Hospital (CN)
Good health and well-being
Gastric Cancer Management and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon